The startup plans to use the funds to scale its single-cell DNA analysis technology for blood-based cancer research and expand into CRISPR applications.
The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.
The company plans to use the funds to drive commercialization of its recently launched Fluidity One instrument and develop other products in its pipeline.
The company said it will use the funds to expand its operations in Ireland, which it established through the recent acquisition of Genomics Medicine Ireland.
The company's first product will use electronic health records, predictive blood-based biomarkers, and other genomic information to guide kidney disease treatment.
The firm's technology uses DNA sequencing, artificial intelligence, and a microbial database to interpret soil health and identify potential disease risk.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
